龙血竭促进糖尿病足创面愈合的作用机制

doi:10.6040/j.issn.1671-9352.0.2025.031

摘要/Abstract

摘要： 采用网络药理学、分子对接和实验验证研究龙血竭促进糖尿病足创面愈合的作用机制。利用TCMSP数据库,筛选龙血竭的化学成分及作用靶标;以“diabetic foot ulcer”“diabetic wound”等为关键词在GeneCards和DisGeNET数据库中检索疾病靶点;取龙血竭成分靶点与疾病靶点交集,构建“成分-疾病-靶标”网络图;生信分析预测龙血竭促进创面愈合的作用机制;采用分子对接考察龙血竭成分与关键靶点的结合情况;采用小鼠巨噬细胞,研究龙血竭及其主要成分对晚期糖基化终产物受体(the receptor of advanced glycation end products, RAGE)蛋白表达的影响。结果表明:网络药理学筛选得到226个化合物疾病共同靶标;KEGG富集分析提示,龙血竭治疗糖尿病足创面的作用可能与AGE-RAGE信号通路密切相关。分子对接结果显示,龙血素A、龙血素B、龙血素C、龙血素D、白藜芦醇、7,4'-二羟基黄酮6个成分与RAGE之间均有较好的结合活性。龙血竭及其主要成分均能显著逆转晚期糖基化终末产物(AGEs)引起的小鼠巨噬细胞RAGE蛋白异常表达。综上,龙血竭促进糖尿病足创面愈合与其调控AGE-RAGE通路,抑制AGEs累积引起RAGE蛋白异常表达相关。

关键词: 龙血竭, 糖尿病足, 网络药理学, 分子对接, 晚期糖基化终产物受体

Abstract: Network pharmacology, molecular docking, and experimental verification were employed to investigate the mechanism by which Resina Draconis promotes the healing of diabetic foot wounds. The TCMSP database was utilized to screen the chemical constituents and targets of Resina Draconis. Disease targets were retrieved from the GeneCards and DisGeNET databases using keywords such as “diabetic foot ulcer” and “diabetic wound”. A “component-disease-target” network diagram was created using the intersections of component targets and disease targets. Bioinformatic analysis predicted the mechanism of Resina Draconis in facilitating wound healing. Molecular docking was used to investigate the combination of the components of Resina Draconis and key targets. Mouse macrophages were used to study the effects of Resina Draconis and its main components on the expression of the receptor of advanced glycation end products(RAGE)protein. The results showed that 226 common disease targets were obtained by network pharmacological screening. KEGG enrichment analysis suggested that the effect of Resina Draconis on diabetic ulcers may be associated with the AGE-RAGE pathway. The results of molecular docking demonstrated that loureirin A, loureirin B, loureirin C, loureirin D, resveratrol, and 7,4'-dihydroxyflavone exhibited good binding activity with the key target RAGE. Resina Draconis and its main components could significantly reverse the abnormal expression of RAGE protein in mouse macrophages induced by advanced glycation end products(AGEs). In conclusion, the mechanism of Resina Draconis in promoting healing of diabetic foot ulcers was associated with the regulation of the AGE-RAGE pathway and the inhibition of the abnormal expression of the RAGE protein caused by the accumulation of advanced glycation end products(AGEs).

Key words: Resina Draconis, diabetic foot, network pharmacology, molecular docking, RAGE

中图分类号:

R285

杨子钰,戴召媛,李根,冯心池. 龙血竭促进糖尿病足创面愈合的作用机制[J]. 《山东大学学报(理学版)》, 2025, 60(9): 31-40.

YANG Ziyu, DAI Zhaoyuan, LI Gen, FENG Xinchi. Mechanism of Resina Draconis in promoting healing of diabetic foot wounds[J]. JOURNAL OF SHANDONG UNIVERSITY(NATURAL SCIENCE), 2025, 60(9): 31-40.

参考文献

[1] ZHOU M G, WANG H D, ZENG X Y, et al. Mortality, morbidity, and risk factors in China and its provinces, 1990—2017: a systematic analysis for the Global Burden of Disease Study 2017[J]. The Lancet, 2019, 394(10204):1145-1158.
[2] ARMSTRONG D G, TAN T W, BOULTON A J M, et al. Diabetic foot ulcers: a review[J]. JAMA, 2023, 330(1):62-75.
[3] FU X B. Wound healing center establishment and new technology application in improving the wound healing quality in China[J]. Burns & Trauma, 2020, 8:38.
[4] HICKS C W, SELVARAJAH S, MATHIOUDAKIS N, et al. Burden of infected diabetic foot ulcers on hospital admissions and costs[J]. Annals of Vascular Surgery, 2016, 33:149-158.
[5] ARMSTRONG D G, BOULTON A J M, BUS S A. Diabetic foot ulcers and their recurrence[J]. New England Journal of Medicine, 2017, 376(24):2367-2375.
[6] SORG H, TILKORN D J, HAGER S, et al. Skin wound healing: an update on the current knowledge and concepts[J]. European Surgical Research Europaische Chirurgische Forschung Recherches Chirurgicales Europeennes, 2017, 58(1/2):81-94.
[7] BURGESS J L, WYANT W A, ABDO ABUJAMRA B, et al. Diabetic wound-healing science[J]. Medicina, 2021, 57(10):1072.
[8] CHANG M, NGUYEN T T. Strategy for treatment of infected diabetic foot ulcers[J]. Accounts of Chemical Research, 2021, 54(5):1080-1093.
[9] 杨敏,杨瑞,覃彬华,等. 民族药龙血竭研究进展[J]. 海峡药学,2019,31(11):49-52. YANG Min, YANG Rui, QIN Binhua, et al. Research progress of dragons blood, a national medicine[J]. Strait Pharmaceutical Journal, 2019, 31(11):49-52.
[10] 孙晶,庞道然,郑姣,等. 龙血竭的药理、临床及质量控制研究进展[J]. 中国医院用药评价与分析,2017,17(11):1445-1447. SUN Jing, PANG Daoran, ZHENG Jiao, et al. Research progress in pharmacology, clinic and quality control of Resina Draconis[J]. Evaluation and Analysis of Drug-Use in Hospitals of China, 2017, 17(11):1445-1447.
[11] FAN J Y, YI T, SZE-TO C M, et al. A systematic review of the botanical, phytochemical and pharmacological profile of Dracaena cochinchinensis, a plant source of the ethnomedicine “dragons blood”[J]. Molecules, 2014, 19(7):10650-10669.
[12] 牟蕾,李秀萍. 龙血竭胶囊治疗糖尿病足溃疡病人的临床研究[J]. 双足与保健,2019,28(13):3-4. MU Lei, LI Xiuping. Clinical study of dragon blood dragon capsule in the treatment of diabetic foot ulcer patients[J]. Biped and Health, 2019, 28(13):3-4.
[13] 孟庆元,林炜栋,陈向芳. AGE-RAGE系统与糖尿病足综合征的发病机制及治疗进展[J]. 药学服务与研究,2009,9(2):118-121. MENG Qingyuan, LIN Weidong, CHEN Xiangfang. The relationship between AGE-RAGE system and pathogenesis of diabetic foot syndrome, and advance on treatment[J]. Pharmaceutical Care and Research, 2009, 9(2):118-121.
[14] BOEZIO B, AUDOUZE K, DUCROT P, et al. Network-based approaches in pharmacology[J]. Molecular Informatics, 2017, 36(10):28692140.
[15] 廖韵诺,赵凯丽,郭宏伟. 中药网络药理学的研究应用与挑战[J]. 中草药,2024,55(12):4204-4213. LIAO Yunnuo, ZHAO Kaili, GUO Hongwei. Application and challenges of network pharmacology research in traditional Chinese medicine[J]. Chinese Traditional and Herbal Drugs, 2024, 55(12):4204-4213.
[16] 林炜栋,陆树良,青春. 糖尿病难愈创面与晚期糖基化终末产物的关系[J]. 中国临床康复,2003,7(17):2491-2493. LIN Weidong, LU Shuliang, QING Chun. The relation between impaired wound healing and advanced glycation end products[J]. Modern Rehabilitation, 2003, 7(17):2491-2493.
[17] LITWINOFF E, HURTADO DEL POZO C, RAMASAMY R, et al. Emerging targets for therapeutic development in diabetes and its complications: the RAGE signaling pathway[J]. Clinical Pharmacology and Therapeutics, 2015, 98(2):135-144.
[18] TAKAHASHI H K, MORI S J, WAKE H, et al. Advanced glycation end products subspecies-selectively induce adhesion molecule expression and cytokine production in human peripheral blood mononuclear cells[J]. The Journal of Pharmacology and Experimental Therapeutics, 2009, 330(1):89-98.
[19] WANG Q, ZHU G Y, CAO X Z, et al. Blocking AGE-RAGE signaling improved functional disorders of macrophages in diabetic wound[J]. Journal of Diabetes Research, 2017, 2017:1428537.
[20] TWARDA-CLAPA A, OLCZAK A, BIAŁKOWSKA A M, et al. Advanced glycation end-products(AGEs): formation, chemistry, classification, receptors, and diseases related to AGEs[J]. Cells, 2022, 11(8):1312.
[21] WU J T, TU M C, ZHUNG P. Advanced glycation end product(AGE): characterization of the products from the reaction between D-glucose and serum albumin[J]. Journal of Clinical Laboratory Analysis, 1996, 10(1):21-34.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed